<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33917182</PMID><DateRevised><Year>2021</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Micafungin Inhibits Dengue Virus Infection through the Disruption of Virus Binding, Entry, and Stability.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">338</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph14040338</ELocationID><Abstract><AbstractText>Dengue fever is an arbovirus disease caused by infection with the dengue virus (DENV). Half of the world's population lives under the threat of dengue fever, however, researchers have yet to develop any drugs that are clinically applicable to this infection. Micafungin is a member of the echinocandins family of anti-fungal drugs, capable of blocking the synthesis of &#x3b2;-1,3-D-glucan in the walls of fungal cells. Previous studies have demonstrated the effectiveness of Micafungin against infections of enterovirus 71 (EV71) and chikungunya virus (CHIKV). This is the first study demonstrating the effectiveness of micafungin in inhibiting the cytopathic effects of dengue virus serotype 2 (DENV-2) in a dose-dependent manner. Time-of-addition assays verified the inhibitory effects of micafungin in pre-treated, co-treated, and full-treatment groups. Binding and entry assays also demonstrated the effectiveness of micafungin in the early stage of DENV-2 infection. The virucidal efficacy of micafungin appears to lie in its ability to destroy the virion. Molecular docking assays revealed the binding of micafungin to the envelope protein of DENV-2, thereby revealing the mechanism by which micafungin affects the early stage of DENV infection and the stability of DENV. Two other micafungin analogs, caspofungin and anidulafungin, were also shown to have the antiviral effects on DENV-2. Finally, immunofluorescence assay (IFA) and reverse-transcription quantitative polymerase chain reaction (RT-qPCR) confirmed the broad anti-DENV ability of micafungin against dengue virus serotypes 1, 3, and 4 (DENV-1, DENV-3, and DENV-4). Taken together, these results demonstrate the potential of micafungin and its analogs as candidates for the development of broad-spectrum treatments for DENV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yen-Chen</ForeName><Initials>YC</Initials><Identifier Source="ORCID">0000-0002-5370-0276</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, National Defense Medical Center (NDMC), No. 161, Section 6, Minquan East Road, Taipei 114, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jeng-Wei</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0003-2128-2046</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, National University of Singapore (NUS), 14 Science Drive 4, Singapore 117543, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeh</LastName><ForeName>Chia-Tsui</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>School of Life Science, National Taiwan Normal University (NTNU), No. 88, Ting-Chow Road, Section 4, Taipei 116, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Preventive Medicine, National Defense Medical Center (NDMC), No. 172, Dapu Road, New Taipei City 237, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Te-Yu</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital (TSGH), National Defense Medical Center (NDMC), No. 161, Section 6, Minquan East Road, Taipei 114, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Feng-Cheng</ForeName><Initials>FC</Initials><AffiliationInfo><Affiliation>Rheumatology/Immunology and Allergy, Department of Internal Medicine, Tri-Service General Hospital (TSGH), National Defense Medical Center (NDMC), No. 161, Section 6, Minquan East Road, Taipei 114, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Yi-Jung</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>School of Pharmacy, National Defense Medical Center (NDMC), No. 161, Section 6, Minquan East Road, Taipei 114, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Life Sciences, National Defense Medical Center (NDMC), No. 161, Section 6, Minquan East Road, Taipei 114, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOST 107-2320-B-016-006-</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>MOST 108-2320-B-016-011-MY2</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country/></Grant><Grant><GrantID>MAB-109-040</GrantID><Agency>Ministry of National Defense-Medical Affairs Bureau, Taiwan</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">binding</Keyword><Keyword MajorTopicYN="N">dengue virus</Keyword><Keyword MajorTopicYN="N">echinocandins</Keyword><Keyword MajorTopicYN="N">entry and virucidal</Keyword><Keyword MajorTopicYN="N">micafungin</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33917182</ArticleId><ArticleId IdType="pmc">PMC8067805</ArticleId><ArticleId IdType="doi">10.3390/ph14040338</ArticleId><ArticleId IdType="pii">ph14040338</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guzman M.G., Gubler D.J., Izquierdo A., Martinez E., Halstead S.B. Dengue infection. Nat. Rev. Dis. Primers. 2016;2:16055. doi: 10.1038/nrdp.2016.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.55</ArticleId><ArticleId IdType="pubmed">27534439</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C., Zhou Z., Wen Z., Liu Y., Zeng C., Xiao D., Ou M., Han Y., Huang S., Liu D., et al. Global Epidemiology of Dengue Outbreaks in 1990&#x2013;2015: A Systematic Review and Meta-Analysis. Front. Cell. Infect. Microbiol. 2017;7:317. doi: 10.3389/fcimb.2017.00317.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2017.00317</ArticleId><ArticleId IdType="pmc">PMC5506197</ArticleId><ArticleId IdType="pubmed">28748176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan S., Jamdar S.F., Alalowi M., Al Ageel Al Beaiji S.M. Dengue virus: A global human threat: Review of literature. J. Int. Soc. Prev. Community Dent. 2016;6:1&#x2013;6. doi: 10.4103/2231-0762.175416.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/2231-0762.175416</ArticleId><ArticleId IdType="pmc">PMC4784057</ArticleId><ArticleId IdType="pubmed">27011925</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler D.J. Dengue and Dengue Hemorrhagic Fever. Clin. Microbiol. Rev. 1998;11:480&#x2013;496. doi: 10.1128/CMR.11.3.480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.11.3.480</ArticleId><ArticleId IdType="pmc">PMC88892</ArticleId><ArticleId IdType="pubmed">9665979</ArticleId></ArticleIdList></Reference><Reference><Citation>Screaton G.R., Mongkolsapaya J., Yacoub S., Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 2015;15:745&#x2013;759. doi: 10.1038/nri3916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3916</ArticleId><ArticleId IdType="pubmed">26603900</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy T., Sansom M.S. The Role of the Membrane in the Structure and Biophysical Robustness of the Dengue Virion Envelope. Structure. 2016;24:375&#x2013;382. doi: 10.1016/j.str.2015.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2015.12.011</ArticleId><ArticleId IdType="pmc">PMC4780862</ArticleId><ArticleId IdType="pubmed">26833387</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P.C. The molecular basis of virulence of the encephalitogenic flaviviruses. J. Gen. Virol. 1997;78:2711&#x2013;2722. doi: 10.1099/0022-1317-78-11-2711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-78-11-2711</ArticleId><ArticleId IdType="pubmed">9367356</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiasny K., Allison S.L., Marchler-Bauer A., Kunz C., Heinz F.X. Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus. J. Virol. 1996;70:8142&#x2013;8147. doi: 10.1128/JVI.70.11.8142-8147.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.70.11.8142-8147.1996</ArticleId><ArticleId IdType="pmc">PMC190891</ArticleId><ArticleId IdType="pubmed">8892942</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicidomini C., Roviello V., Roviello G.N. Molecular Basis of the Therapeutical Potential of Clove (Syzygium aromaticum L.) and Clues to Its Anti-COVID-19 Utility. Molecules. 2021;26:1880. doi: 10.3390/molecules26071880.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26071880</ArticleId><ArticleId IdType="pmc">PMC8036487</ArticleId><ArticleId IdType="pubmed">33810416</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K., Zilbermintz L., Martchenko M. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans. Ann. Clin. Microbiol. Antimicrob. 2015;14:1&#x2013;11. doi: 10.1186/s12941-015-0090-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-015-0090-4</ArticleId><ArticleId IdType="pmc">PMC4462072</ArticleId><ArticleId IdType="pubmed">26054754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C., Kang H., Kim D.-E., Song J.-H., Choi M., Kang M., Lee K., Kim H.S., Shin J.S., Jeong H., et al. Antiviral activity of micafungin against enterovirus 71. Virol. J. 2016;13:1&#x2013;9. doi: 10.1186/s12985-016-0557-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0557-8</ArticleId><ArticleId IdType="pmc">PMC4907259</ArticleId><ArticleId IdType="pubmed">27296985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho Y.-J., Liu F.-C., Yeh C.-T., Yang C.M., Lin C.-C., Lin T.-Y., Hsieh P.-S., Hu M.-K., Gong Z., Lu J.-W. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms. Antivir. Res. 2018;159:134&#x2013;142. doi: 10.1016/j.antiviral.2018.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.10.005</ArticleId><ArticleId IdType="pubmed">30300716</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho Y.-J., Wang Y.-M., Lu J.-W., Wu T.-Y., Lin L.-I., Kuo S.-C., Lin C.-C. Suramin Inhibits Chikungunya Virus Entry and Transmission. PLoS ONE. 2015;10:e0133511. doi: 10.1371/journal.pone.0133511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133511</ArticleId><ArticleId IdType="pmc">PMC4514758</ArticleId><ArticleId IdType="pubmed">26208101</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto S. Micafungin: A sulfated echinocandin. J. Antibiot. 2009;62:27&#x2013;35. doi: 10.1038/ja.2008.3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ja.2008.3</ArticleId><ArticleId IdType="pubmed">19132058</ArticleId></ArticleIdList></Reference><Reference><Citation>Denning D.W. Echinocandin antifungal drugs. Lancet. 2003;362:1142&#x2013;1151. doi: 10.1016/S0140-6736(03)14472-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)14472-8</ArticleId><ArticleId IdType="pubmed">14550704</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross S.A., Scott L.J. Micafungin: A review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections. Drugs. 2008;68:2225. doi: 10.2165/00003495-200868150-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200868150-00010</ArticleId><ArticleId IdType="pubmed">18840009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q.-Y., Patel S.J., Vangrevelinghe E., Xu H.Y., Rao R., Jaber D., Schul W., Gu F., Heudi O., Ma N.L., et al. A Small-Molecule Dengue Virus Entry Inhibitor. Antimicrob. Agents Chemother. 2009;53:1823&#x2013;1831. doi: 10.1128/AAC.01148-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01148-08</ArticleId><ArticleId IdType="pmc">PMC2681551</ArticleId><ArticleId IdType="pubmed">19223625</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wispelaere M., Lian W., Potisopon S., Li P.-C., Jang J., Ficarro S.B., Clark M.J., Zhu X., Kaplan J.B., Pitts J.D., et al. Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein. Cell Chem. Biol. 2018;25:1006&#x2013;1016. doi: 10.1016/j.chembiol.2018.05.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2018.05.011</ArticleId><ArticleId IdType="pmc">PMC6097893</ArticleId><ArticleId IdType="pubmed">29937406</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Kai E.L.J., Lu L. Investigating the stability of dengue virus envelope protein dimer using well-tempered metadynamics simulations. Proteins Struct. Funct. Bioinform. 2019;88:643&#x2013;653. doi: 10.1002/prot.25844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prot.25844</ArticleId><ArticleId IdType="pubmed">31697409</ArticleId></ArticleIdList></Reference><Reference><Citation>Higa Y. Dengue Vectors and their Spatial Distribution. Trop. Med. Health. 2011;39:S17&#x2013;S27. doi: 10.2149/tmh.2011-S04.</Citation><ArticleIdList><ArticleId IdType="doi">10.2149/tmh.2011-S04</ArticleId><ArticleId IdType="pmc">PMC3317606</ArticleId><ArticleId IdType="pubmed">22500133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hon&#xf3;rio N.A., Wiggins K., C&#xe2;mara D.C.P., Eastmond B., Alto B.W. Chikungunya virus vector competency of Brazilian and Florida mosquito vectors. PLOS Negl. Trop. Dis. 2018;12:e0006521. doi: 10.1371/journal.pntd.0006521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0006521</ArticleId><ArticleId IdType="pmc">PMC6007930</ArticleId><ArticleId IdType="pubmed">29879121</ArticleId></ArticleIdList></Reference><Reference><Citation>White J.M., Delos S.E., Brecher M., Schornberg K. Structures and Mechanisms of Viral Membrane Fusion Proteins: Multiple Variations on a Common Theme. Crit. Rev. Biochem. Mol. Biol. 2008;43:189&#x2013;219. doi: 10.1080/10409230802058320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10409230802058320</ArticleId><ArticleId IdType="pmc">PMC2649671</ArticleId><ArticleId IdType="pubmed">18568847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasmann R.E., Muilwijk E.W., Burger D.M., Verweij P.E., Knibbe C.A., Br&#xfc;ggemann R.J. Clinical Pharmacokinetics and Pharmacodynamics of Micafungin. Clin. Pharmacokinet. 2017;57:267&#x2013;286. doi: 10.1007/s40262-017-0578-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-017-0578-5</ArticleId><ArticleId IdType="pmc">PMC5814521</ArticleId><ArticleId IdType="pubmed">28791666</ArticleId></ArticleIdList></Reference><Reference><Citation>Gumbo T. Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna! Clin. Infect. Dis. 2015;61:S635&#x2013;S642. doi: 10.1093/cid/civ715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ715</ArticleId><ArticleId IdType="pubmed">26567282</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu P.-Y., Chang S.-F., Kuo Y.-C., Yueh Y.-Y., Chien L.-J., Sue C.-L., Lin T.-H., Huang J.-H. Development of Group- and Serotype-Specific One-Step SYBR Green I-Based Real-Time Reverse Transcription-PCR Assay for Dengue Virus. J. Clin. Microbiol. 2003;41:2408&#x2013;2416. doi: 10.1128/JCM.41.6.2408-2416.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.41.6.2408-2416.2003</ArticleId><ArticleId IdType="pmc">PMC156548</ArticleId><ArticleId IdType="pubmed">12791857</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y., Ogata S., Clements D.E., Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. USA. 2003;100:6986&#x2013;6991. doi: 10.1073/pnas.0832193100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0832193100</ArticleId><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneidman-Duhovny D., Inbar Y., Nussinov R., Wolfson H.J. PatchDock and SymmDock: Servers for rigid and symmetric docking. Nucleic Acids Res. 2005;33:W363&#x2013;W367. doi: 10.1093/nar/gki481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gki481</ArticleId><ArticleId IdType="pmc">PMC1160241</ArticleId><ArticleId IdType="pubmed">15980490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai Z.-Z., Ho Y.-J., Lu J.-W. Harringtonine Inhibits Zika Virus Infection through Multiple Mechanisms. Molecules. 2020;25:4082. doi: 10.3390/molecules25184082.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules25184082</ArticleId><ArticleId IdType="pmc">PMC7570876</ArticleId><ArticleId IdType="pubmed">32906689</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J.-W., Hsieh P.-S., Lin C.-C., Hu M.-K., Huang S.-M., Wang Y.-M., Liang C.-Y., Gong Z., Ho Y.-J. Synergistic effects of combination treatment using EGCG and suramin against the chikungunya virus. Biochem. Biophys. Res. Commun. 2017;491:595&#x2013;602. doi: 10.1016/j.bbrc.2017.07.157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2017.07.157</ArticleId><ArticleId IdType="pubmed">28760340</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>